Advanced Biodesign
- Biotech or pharma, therapeutic R&D
Advanced BioDesign’s research embodies a novel and highly creative approach to overcoming one of oncology’s most persistent challenges: drug resistance by targeting of ALDH1, a key enzyme in cancer cell survival by detoxifying cytotoxic agents and neutralizing oxidative stress — mechanisms that allow malignant cells to evade the effects of chemotherapy and radiotherapy. Our lead compound, ABD-3001, selectively inhibits ALDH1 activity, disrupting cancer cell metabolism and triggering apoptosis while preserving healthy tissue. This first-in-class mechanism offers a transformative solution to chemoresistance, particularly in Acute Myeloid Leukemia, where relapse and treatment failure remain devastatingly common. By extending this platform to solid tumors and combination regimens, Advanced BioDesign is pioneering a scalable, mechanism-driven therapeutic paradigm that redefines how resistance is tackled in cancer care — showcasing both scientific ingenuity and clinical impact.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}